Patents by Inventor Julius S. Horoszewicz

Julius S. Horoszewicz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of detecting prostate carcinoma using a monoclonal antibody to a new antigenic marker in epithelial prostatic cells alone or with a monoclonal antibody to an antigen of LNCaP cells
    Patent number: 5763202
    Abstract: Monoclonal antibodies to prostatic cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies show specificity for a non-soluble, membrane associated, organ specific antigenic determinant limited in its distribution to human prostate epithelial cells and normal prostatic epithelial cells. The monoclonal antibodies, specifically, 7Ell monoclonal antibodies, can be used diagnostically and therapeutically.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 9, 1998
    Assignee: Cytogen Corporation
    Inventor: Julius S. Horoszewicz
  • Hybridoma and monoclonal antibody 9H10-A4 specific to an antigen of LNCaP cells
    Patent number: 5578484
    Abstract: Monoclonal antibodies, specifically 9H10-A4 monoclonal antibodies, specific to an epitope present on the surface of LNCaP cells, are produced by hybridoma cell line 9H10-A4 formed by fusing mouse lymphocytes and mouse myeloma cells. 9H10-A4 monoclonal antibodies are useful to positively identify LNCaP cells and distinguish them from other cultured cells, and as a reliable control in competitive binding studies for detection of circulating antigens associated with prostate carcinoma.
    Type: Grant
    Filed: September 16, 1994
    Date of Patent: November 26, 1996
    Assignee: Cytogen Corporation
    Inventor: Julius S. Horoszewicz
  • Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
    Patent number: 5162504
    Abstract: Monoclonal antibodies to prostatic cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies show specificity for a non-soluble, membrane associated, organ specific antigenic determinant limited in its distribution to normal and neoplastic, human prostate epithelial cells. The monoclonal antibodies, specifically 7E11-C5 monoclonal antibodies, may be suitable for diagnostic uses.
    Type: Grant
    Filed: June 3, 1988
    Date of Patent: November 10, 1992
    Assignee: Cytogen Corporation
    Inventor: Julius S. Horoszewicz